For Lykos Therapeutics and the company’s would-be MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the hits just keep coming.

Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in patients with cognitive dysfunction and major depressive disorder.

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development.

Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off.

While the biotech investment scene in Europe has slowed somewhat following a COVID-19 funding boom in 2021, a new report from PitchBook suggests venture capital firms looking at opportunities across the pond could soon have more cash to spare.

After raising $213 million in 2023—one of the year’s largest private biotech rounds—Tome Biosciences is making cuts.

Venture capital funding into biopharma rose to $9.2 billion across 215 deals in the second quarter of this year, reaching the highest funding level since the same quarter in 2022.

BioAge Labs has appointed former GSK CEO Jean-Pierre Garnier as chair of its board of directors, bringing the pharma veteran back into the anti-aging space 16 years after he made a big bet on the sector.

On the heels of a June 17 paper showing a small molecule’s ability to declutter pathological protein buildups in the brain, researchers from the University of California, San Diego (UCSD) and the University of Pennsylvania have received a $6.9 million grant from the National Institute on Aging to prepare the drug for clinical trials.

BridgeBio Pharma is once again spinning out a chunk of its pipeline, this time offloading a handful of early-stage genetic disease programs to a new company called GondolaBio.